Biosimilars finally taking off in the US
Usage of Biosimilars has increased significantly in Europe, while usage in the US has been lagging behind.
Now, Biosimilars are finally taking off in the US thanks to Oncology blockbusters Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin) and Infliximab (Remicade), creating a massive market opportunity.
